Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 13/20 | 0.39 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.36 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22137903 | 0.91 | RET (0.39) | RETMETCCNCCDK8TTK | |
| SCHEMBL22137913 | 0.91 | MET (0.40) | RETMETCCNCCDK8TTK | |
| SCHEMBL22138085 | 0.88 | RET (0.46) | RET | |
| Hydrochloric Acid SCHEMBL22118679 | 0.87 | RET (0.46) | RET | |
| SCHEMBL22138077 | 0.86 | RET (0.40) | RETMET | |
| SCHEMBL22137905 | 0.85 | RET (0.43) | RETMETPAK1MAP4K3 | |
| SCHEMBL29434952 | 0.82 | RET (0.53) | RETMETCCNCCDK8TTK | |
| SCHEMBL22118566 | 0.81 | RET (0.48) | RETMETCCNCCDK8TTK | |
| SCHEMBL22137951 | 0.81 | RET (0.40) | RETMET | |
| SCHEMBL22138082 | 0.81 | RET (0.40) | RETMETTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
| WO-2020131627-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | FGFR1, FGFR4, FGFR3 | RET 11/4885MET 184/4885CCNC 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.